[Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause].
Triptans, 5-HT1B/1D agonists used in migraine treatment, are rarely involved in serious coronary events due to vasospasm. 5 HT1 receptors mediate vasodilation and vasoconstriction of coronary arteries. Reports of serious coronary events mainly concern patients with known risk factors for coronary artery disease. It is prudent to obtain a thorough medical history before treatment with a triptan is started. If chest pain occurs, the possibility of coronary ischemia should be investigated. Stroke, a known complication to migraine, has also been reported in patients treated with triptans, but available data do not suggest that triptans, when correctly used, greatly increase the risk.